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Abstract 
Background: The causative link between UV exposure and melanoma development is well known, however the 
mechanistic relationship remains incompletely characterised. UVA and UVB components of sunlight are implicated in 
melanomagenesis; however the majority of studies have focused on the effects of UVB and UVC light. Interestingly, 
melanoma tumour sequencing has revealed an overrepresentation of mutations signature of unrepaired UV-induced 
DNA damage. Repair of UVA-induced DNA damage is thought to occur primarily through the Nucleotide Excision 
Repair (NER) pathway, which recognises and repairs damage either coupled to transcription (Transcription Coupled 
Repair; TCR), or through global genome scanning (Global Genome Repair; GGR). Current literature suggests NER is 
deficient in melanoma, however the cause of this remains unknown; and whether reduced NER activity in response 
to UVA may be involved in melanoma development remains uncharacterised. In this study we aimed to determine if 
melanoma cells exhibit reduced levels of NER activity in response to UVA.
Methods: Melanocyte and melanoma cell lines were UVA-irradiated, and DNA damage levels assessed by immu-
nodetection of Cyclobutane Pyrimidine Dimer (CPD) and (6-4) Photoproduct [(6-4)PP] lesions. Expression of NER 
pathway components and p53 following UVA treatment was quantified by qPCR and western blot.
Results: UVA did not induce detectable induction of (6-4)PP lesions, consistent with previous studies. Repair of CPDs 
induced by UVA was initiated at 4 h and complete within 48 h in normal melanocytes, whereas repair initiation was 
delayed to 24 h and >40 % of lesions remained in melanoma cell lines at 48 h. This was coupled with a delayed and 
reduced induction of GGR component XPC in melanoma cells, independent of p53.
Conclusion: These findings support that NER activity is reduced in melanoma cells due to deficient GGR. Further 
investigation into the role of NER in UVA-induced melanomagenesis is warranted and may have implications for mela-
noma treatment.
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Background
Melanoma derives from the malignant transformation of 
melanocytes [1, 2]. Cutaneous melanoma, or melanoma 
of the skin, represents the most common form of the dis-
ease; accounting for more than 90 % of cases [3]. Cuta-
neous melanoma tumours are commonly non-responsive 
to standard DNA-damaging chemotherapeutic agents. 
Targeted therapies to the BRAF V600E mutation present 
in 30–60 % of metastatic melanomas [4, 5] and immune-
therapy based approaches display the highest treatment 
response rates [6, 7].
UV light exposure is estimated to be causative of more 
than 90 % of cutaneous melanoma cases [8]. Despite this, 
the mechanism by which UV light leads to melanoma 
development remains incompletely characterised. The 
UV spectrum is subdivided into UVC (100–280  nm), 
UVB (280–315  nm), and UVA (315–400  nm) light but 
UVA constitutes approximately 95  % of environmental 
UV exposure with UVB making up the remaining 5 % [9, 
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10]. The relatively lower energy UVA rays penetrate deep-
est into the skin; therefore, UVA is estimated to account 
for 99  % of UV that melanocyte skin cells are naturally 
exposed to [11, 12].
Despite its environmental abundance, the UVA com-
ponent of the UV spectrum is understudied. Until recent 
years UVA exposure was considered non-harmful, with 
UVA doses in the range of 100,000 J/m2 required to pro-
duce comparable cellular effects as UVB doses approxi-
mately 100 fold lower, and UVC doses 10,000 fold lower 
[13–15]. Epidemiological assessments of human mela-
noma incidence as a function of environmental UV expo-
sure have reported that UVA exposure is an independent 
risk factor for melanoma development [16–18]. Consist-
ent with this, UVA tanning bed use has been associated 
with an increased risk of developing melanoma [19–22]. 
The International Agency for Research in Cancer (IARC) 
now recognises UVA as a class I carcinogen [23].
UV radiation induces two main forms of DNA dam-
age: pyrimidine dimers and oxidative base damage. 
Pyrimidine dimers are formed by direct absorption of 
UV energy by DNA, leading to the formation of covalent 
bonding between contiguous pyrimidine bases [24, 25]. 
This results in either a Cyclobutane Pyrimidine Dimer 
(CPD) or (6-4) Pyrimidine Pyrimidone [(6-4)PP] struc-
ture [26]. CPD and (6-4)PP lesions both distort the helical 
structure of DNA, forming substrates for the DNA repair 
process, known as nucleotide excision repair (NER) [27]. 
Left unrepaired, C > T transition mutations often result 
due to the misincorporation of Adenine opposite the 
lesion. As such, C > T transitions are considered UV ‘sig-
nature’ mutations [28].
NER is a vital DNA repair process that detects and 
repairs lesions that cause both chemical alteration and 
structural distortion of the DNA helix [27] such as CPDs, 
6-4PPs and platinum-based chemotherapy induced DNA 
crosslinks. The NER pathway possesses two different 
mechanisms for detection of DNA damage; Transcrip-
tion Coupled Repair (TCR) and Global Genome Repair 
(GGR; for extensive review, see [29–32]). TCR detects 
lesions in transcribed sections of the genome; triggered 
when a lesion inhibits transcription elongation by RNA 
polymerase II. GGR detects lesions across the whole 
genome, including non-transcribed regions. Upon lesion 
detection by either the TCR or GGR arm, repair pro-
ceeds via a final common pathway [33]. Pathogenic muta-
tions in the GGR components XPC and DDB2 (XPE) 
result in xeroderma pigmentosum (XP) a disease char-
acterised by increased UV-sensitivity and skin cancer 
incidence. Conversely, mutation in TCR genes ERCC8 
(CSA) and ERCC6 (CSB) result in Cockayne’s syndrome 
that is characterised by neurological abnormalities but 
no increase in skin cancer incidence. Some NER proteins, 
particularly the GGR damage recognition proteins, can 
decide a cell’s fate by triggering the initiation of the repair 
pathway or by signalling apoptosis [34]. Therefore, if the 
GGR pathway is defective, neither DNA repair nor apop-
tosis occurs, resulting in a cancer cell containing high 
levels of UV-induced mutations that does not undergo 
apoptosis, both of which are features of melanoma [35].
The majority of research characterising the NER 
response to UV has been performed using UVB and 
UVC. CPD lesion removal following UVA has been 
assessed in keratinocytes [36] and human skin [37], how-
ever the NER response to UVA has not been character-
ised at the transcript or protein level, for any cell type. 
The current literature suggests that NER, and in particu-
lar the global genome repair (GGR) damage recognition 
sub-group [38, 39], may be deficient in melanoma. The 
effect this has on repair of UVA-induced DNA damage in 
melanoma is unknown. In this study we aimed to deter-
mine if melanoma cells exhibit reduced levels of NER 
activity in response to UVA. We quantified expression 
of the entire NER pathway, and confirmed altered activ-
ity of the GGR components XPC, DDB1, DDB2, and p53 
following UVA treatment; and CPD and (6-4)PP lesion 




The non-transformed Human Epidermal Melanocyte 
adult Lightly Pigmented cell strain HEMaLP was pur-
chased from Life Technologies. Metastatic melanoma 
cell line Mel-RM and primary melanoma cell lines Sk-
Mel-28, MM200, and Me4405 were derived as described 
previously [40, 41]. The mutation status of these cell lines 
for p53 are: Mel-RM wild-type, Sk-mel-28 p53 R273H, 
MM200 p53 wild-type and Me4405 p53 null.
Cells were maintained in standard culture conditions at 
5 % CO2, 37  °C. Melanocytes were cultured in Medium 
254 containing human melanocyte growth supplement 
(HMGS; Life Technologies). Melanoma cells were cul-
tured in 1× complete DMEM (Gibco, Life Technologies;) 
supplemented with 10 % FBS (SAFC Biosciences, Sigma-
Aldrich), All cell lines were routinely confirmed to be free 
of mycoplasma contamination. Authentication of cell 
lines was performed by the Australian Genome Research 
Facility using the GenePrint 10 system.
UVA treatment
Cells at confluence were UVA-irradiated using a Grobel 
Irradiation Chamber (Dr. Gröbel UV-Elektronik GmbH, 
Germany) at 100 kJ/m2. This is a physiologically relevant 
dose of UVA; attainable in approximately an hour of sum-
mer sun exposure [10]. 100 kJ/m2 UVA was also sufficient 
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to induce a low level of cell death in the majority of cell 
lines across 48 h following irradiation (data not shown).
DNA damage detection
CPD and (6-4)PP lesions were quantified using an infra-
red immunodetection microplate assay, as previously 
described [42] with some modifications. Cells were 
grown to confluence in 96 well plates, irradiated with 
UVA and incubated for the required time period (0, 1, 
4, 24, or 48 h). Cells were then fixed and permeabilised 
by incubation in prechilled 1:1 methanol/acetone, for 
10 min at −20 °C. Plates were washed twice in PBS, fol-
lowed by denaturation of cellular DNA by incubation in 
hydrochloric acid (HCl) for 30 min at room temperature. 
DNA denaturation with 2 M HCl was determined to be 
optimal for CPD detection, and 0.5  M HCl for (6-4)PP 
detection. Following two washes in PBS-TB (0.1 % Tween 
20, 1 % BSA), blocking PBS-TB for 90 min at room tem-
perature, cells were probed for DNA damage levels by 
overnight incubation at 4  °C with anti-(6-4)PP antibody 
(1:1000; clone KTM50, Kamiya Biomedical Company) 
or anti-CPD antibody (1:1000; clone KTM53) diluted in 
PBS-TB.
Plates were then washed five times in PBS-TB and 
incubated with secondary antibody (1:800 IRDye goat-
anti-mouse 800CW; LI-COR) for 1  h at room tempera-
ture. Cells were concurrently stained with the infrared 
non-specific cellular stain CellTag700 (1:500; LI-COR), to 
enable normalisation of the damage signal to cell number. 
Following five washes in PBS-T, plates were scanned on 
a LI-COR Odyssey CLx infrared imager. Quantification 
was performed using Image Studio (LI-COR). Standard 
curves were run to ensure CPD, (6-4)PP and CellTag700 
signal was measured in the linear range (data not shown).
NER transcript expression
RNA was extracted using TRIzol reagent (Invitrogen) 
as per manufacturer’s instructions, or in combination 
with an RNeasy kit (Qiagen). Melanin contaminated 
RNA samples were purified using OneStep PCR inhibi-
tor removal kits (Zymo Research). RNA was reverse 
transcribed using High Capacity cDNA Reverse Tran-
scription Kits (Applied Biosystems). A standardised 
amount of RNA (2ug) was reverse transcribed for all 
samples. Resultant cDNA was diluted to a 1:20 working 
concentration.
The expression of 13 NER transcripts, p53 
(Hs00153340_m1) and two housekeeping (endogenous 
control) transcripts GAPDH (4326317E) and β-actin 
(4326215E) were quantified using Taqman Gene Expres-
sion Assays (Applied Biosystems) and a ViiA7 (Applied 
Biosystems). NER transcripts assays: XPC (Hs01104206_
m1), DDB1 (Hs00172410_m1), DDB2 (Hs00172068_m1), 
CSA/ERCC8 (Hs01122123_m1), CSB/ERCC6 
(Hs00972920_m1), XPD/ERCC2 (Hs00361161_
m1), XPB/ERCC3 (Hs01554450_m1), XPG/ERCC5 
(Hs00164482_m1), XPF/ERCC4 (Hs00193342_m1), 
ERCC1 (Hs01012158_m1), XPA (Hs00166045_m1), 
RPA1 (Hs00161419_m1), RPA2 (Hs00358315_m1).
NER transcript expression was normalised relative to 
the endogenous control GAPDH. Of the housekeeping 
genes quantified, GAPDH demonstrated the lowest vari-
ability in expression. GAPDH expression was not modu-
lated by treatment; this was verified by determining the 
ratio of expression compared to that of β-actin. Average 
GAPDH/β-actin ratio across all samples was 0.90 ± 0.002 
(average ± SEM).
Relative expression (RE) was calculated by 2−∆Ct [43]. 
Induction (fold change) of expression from baseline was 
calculated by dividing by the baseline RE value; induc-
tion at baseline was by definition set at 1. Induction val-
ues less than 1 were converted to negative values. RE and 
induction results represent the mean of triplicate deter-
minations of three independent experiments, ±SEM. 
For further analysis melanoma cell lines were grouped by 
p53 status, and averaged results for p53 wildtype (p53+; 
MM200 and Mel-RM) and p53 mutant/null (p53−; SK-
Mel-28 and Me4405 respectively).
NER protein expression
Whole cell extracts were prepared in, RIPA buffer 
(50  mM Tris–HCl pH 7.5, 150  mM NaCl, 1  % NP-40, 
0.5  % sodium deoxycholate, 0.1  % SDS) containing 
complete mini protease inhibitors (Roche). Cells were 
lysed, insoluble material was pelleted by centrifuga-
tion (5 min, 12,000 rpm) and the supernatant collected. 
Protein quantification was performed by bicinchoninic 
acid (BCA) assay, as per manufacturer’s instructions 
(Thermo-Scientific).
XPC (Santa Cruz A-5, 1:250), DDB1 (Invitrogen 
ZD001, 1:1000), DDB2 (Abcam 2246C4, 1:50), and p53 
(Abcam DO-1, 1:500) were assessed by SDS-PAGE fol-
lowed by western blot using GAPDH (Abcam EPR6256, 
1:1000) as a loading control. p53 and GAPDH primary 
antibodies were detected using IRDye labelled goat-
anti-mouse (LI-COR) and goat-anti-rabbit (LI-COR) 
respectively. Blots were then visualised on a LI-COR 
Odyssey CLx infrared imager. DDB1, DDB2, and XPC 
were detected using goat-anti-mouse HRP-conjugated 
secondary antibody (1:15,000; Biorad) and developed 
by incubation in SuperSignal West Femto Chemilumi-
nescent substrate (ThermoFisher) and developed on a 
FujiFilm LAS3000 imager (FujiFilm Medical Systems). 
All blot images underwent densitometry analysis using 
Image Studio v3.1 (LI-COR). Quantification was per-
formed by normalisation to GAPDH and expressed as 
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fold induction from baseline. Standard curves were run 
for all proteins of interest, to ensure detection was in the 
linear range (data not shown).
Statistical analysis
Non-parametric Mann–Whitney U tests were performed 
with SPSS software (IBM corporation), and obtained p 
values were corrected for multiple comparisons using 
the Holm-Sidak approach. p  <  0.05 was considered 
significant.
Results
Melanoma cells are slower to repair CPD lesions caused 
by UVA damage
To quantify DNA damage induced by UVA cell lines were 
irradiated with a solar available dose of UVA (100 kJ/m2) 
and antibody-mediated detection of CPD and (6-4)PP 
lesions was used for quantification. Consistent with pre-
vious reports, 100 kJ/m2 UVA did not induce detectable 
(6-4)PP (Fig. 1a) but did induce CPD lesions, at a similar 
level to 600 J/m2 UVB (Fig. 1b).
Melanocytes completed repair of CPD lesions within 
48 h following exposure to 100 kJ/m2 UVA, with almost 
50 % of repair occurring by 1 h, followed by the remain-
der of repair occurring after 4  h (Fig.  2). All the mela-
noma cell lines displayed a higher level of CPD lesions 
at all time points following UVA exposure when com-
pared to melanocytes, reaching significant difference at 1 
(p = 0.02), 24 (p = 0.02) and 48 h (p = 0.008). In all of the 
melanoma cell lines the majority of repair occurred after 
the 24 h time point, with more than 40 % of CPD lesions 
remaining at 48  h in all melanoma cell lines (Fig.  2). 
Between melanoma cell lines, no significant differences 
in repair rate were observed.
Melanoma cells have delayed expression of GGR 
in response to UVA damage
To determine if NER deficiency was responsible for the 
lack of CPD repair in melanoma the relative expression of 
13 NER pathway mRNA transcripts, and the NER regula-
tor p53, were subsequently quantified. Of these, a marked 
difference between melanocyte and melanoma cell lines 
was identified for p53 and the three GGR transcripts 
XPC, DDB1, and DDB2. The remainder of the NER path-
way transcripts showed no consistent changes in expres-
sion between melanocytes and melanoma (Table 1).
XPC transcript displayed a bimodal induction pattern, 
with expression peaking at 4 and 48 h (Fig. 3a) and was 
significantly higher in melanocytes compared to all mela-
noma cell lines, at 4 h following UVA exposure (Fig. 3a). 
Similarly, XPC protein peaked at 4 and 24  h (Fig.  3d). 
The XPC expression directly aligned with the majority 
of CPD repair occurring after 4 h in melanocytes (Fig. 2). 
In comparison, melanoma cells displayed a delayed 
response, with transcript expression peaking at 24 or 
48 h (Fig. 3a) and XPC protein peaking at 24 h in all cell 
lines except Me4405 (Fig.  3d). The XPC expression in 
melanoma also reflected the CPD repair occurring pre-
dominantly after 24 h in all melanoma cell lines (Fig. 2).
DDB1 transcript expression was significantly higher 
in melanocytes at all time points (Fig. 3b), particularly 4 
and 48 h post-UVA. Following a slight decline 1 h post-
UVA, DDB1 protein expression was increased in mel-
anocytes in response to UVA, with maximal induction 
at 48 h. Two (Sk-Mel-28, Mel-RM) of four melanoma cell 
lines displayed a DDB1 protein induction profile com-
parable to this (Fig.  3d). Similarly, DDB2 transcript lev-
els were significantly higher in melanocytes at almost all 
time points, in particular at 4 and 48 h (Fig. 3c). The same 
trend occurred at 24  h, but did not reach significance. 
DDB2 protein abundance was low in all cell lines, only 
slight increase were detected in each of the cell lines at 
various timepoints (Fig.  3d). In summary, XPC expres-
sion most accurately reflected the delay in CPD repair in 
melanoma.
GGR deficiency in melanoma is independent of p53
p53 is known to directly regulate NER function, [44, 
45]. However, XPC [46] and DDB2 [47] may also affect 
expression of p53, suggesting the presence of a feedback 
loop. In addition, XPC and DDB2 also function indepen-
dently of p53 to induce apoptosis [48, 49]. To investigate 
the possible regulatory relationship between p53 and the 
GGR deficiency in melanoma, p53 transcript and pro-
tein was quantified after UVA and p53 mutation status 
was investigated in relation to NER levels. p53 transcript 
levels were higher at all timepoints in melanocytes, sig-
nificant for all cell lines at 1 and 4 h (p < 0.05) (Fig. 4a) 
but p53 protein was only detectable at very low levels in 
melanocytes at 4 and 24 h post-UVA. Interestingly, with 
the exception of Me4405 (p53 null) all melanoma cell 
lines displayed low p53 transcript expression with slight 
increases at 48  h after UVA. Sk-Mel-28 has a gain of 
oncogenic function mutation in p53 (R273H), and along 
with MM200 and Mel-RM an increase in post-UVA 
p53 protein was detected (Fig.  4). Sk-mel-28 was the 
only melanoma cell line to have p53 protein detectable 
at baseline, before UVA. Despite large variations in p53 
expression and reported activity from completely null 
p53 (Me4405) to gain of oncogenic function (Sk-mel-28) 
there was no significant differences in repair rates of 
CPDs across all of the melanoma cell lines.
Despite the similar CPD repair rates, significant dif-
ferences in DDB1 and DDB2 transcript expression were 
observed by p53 mutation status. DDB1 expression was 
significantly higher in p53 mutant/null (Sk-Mel-28, 
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Me4405; p53− melanoma) compared to p53 wildtype 
(MM200, Mel-RM; p53+  melanoma) cell lines at base-
line, and 1 and 24  h following UVA exposure (Fig.  5). 
Conversely, DDB2 transcript expression was significantly 
lower in p53- melanoma cells at all time points (Fig. 5). 
No significant difference in XPC expression was observed 
based on p53 status (Fig. 5). The significant difference due 
to p53 status was not seen at the protein level for XPC, 
DDB1, DDB2 or in the rate of CPD removal, confirming 
that the GGR deficiency in melanoma is independent of 
p53.
In summary, Melanocytes were observed to complete 
repair of CPDs within 48 h following UVA exposure, with 
the majority of repair occurring after the 4 h time point. 
Preceding this, melanocytes had a marked induction of 
NER transcripts at 4 h, specifically, the GGR transcripts 
Fig. 1 Immunodetection of (6-4)PP and CPD induction in response to UVA and UVB. Melanoma (Me4405, Sk-Mel-28) cell lines were irradiated with 
UVA or UVB, and DNA damage lesions were quantified at 0 h. a (6-4)PP and b CPD quantitation and corresponding raw images. Signal was normal-
ised to cell number; points mean of three independent experiments, bars SEM. Images depict cell stain signal (red, 700 nm channel) overlaid with 
the DNA damage signal (green, 800 nm channel)
Fig. 2 CPD repair after UVA in melanocytes and melanoma. Melano-
cyte (HEMaLP) and melanoma cell lines (MM200, Sk-Mel-28, Me4405, 
Mel-RM) were irradiated with 100 kJ/m2 UVA, and CPD lesions quanti-
fied following irradiation. Results are shown as a percentage of 0 h. 
Bars mean of four independent experiments ± SEM. Significance 
determined by Mann–Whitney U test for all melanoma cell lines 
compared to melanocytes (HEMaLP) *p < 0.01
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XPC, DDB1, and DDB2. UVA irradiation also elicited 
induction of GGR and p53 protein expression in mel-
anocytes. Conversely, removal of CPD photoproducts 
was slower, commencing at 24 h and incomplete in mela-
noma cells at 48 h after UVA exposure. The GGR com-
ponent XPC displayed significantly lower induction in 
melanoma, which was independent of p53 mutation or 
expression.
Discussion
UVA constitutes the majority of solar UV (>95  %) [10] 
and exposure is linked to melanoma incidence [16–18], 
but the mechanistic relationship remains incompletely 
characterised. UVA induces DNA damage in the form 
of CPD lesions that are primarily repaired by the NER 
pathway; however, the NER response to UVA is unchar-
acterised in melanoma. Here we show that NER of UVA-
induced CPDs is deficient in melanoma cells compared to 
normal melanocytes. We find that this is correlated with 
altered XPC expression, which is independent of p53 
expression.
Consistent with previous reports [26, 50], UVA irra-
diation did not induce a detectable increase in (6-4)PP 
lesions. Irradiation with a solar available dose of UVA 
(100 kJ/m2) was observed to induce a similar level of CPD 
lesions as a high dose of UVB (600 J/m2). This highlights 
that although UVA rays are lower energy than UVB rays, 
the high level of environmental UVA exposure equates to 
a dose that induces a high level of DNA damage.
In comparison to normal melanocytes, melanoma cells 
displayed a delayed and attenuated DNA repair response 
to UVA (Fig.  2). Whilst melanocytes completed CPD 
repair within 48 h, more than 40 % of lesions remained 
in all melanoma cell lines at 48  h following irradiation. 
In melanocytes, the majority of repair occurred after the 
4 h time point; whereas in melanoma cells the majority 
of repair occurred after 24  h. The relative deficiency in 
NER activity in melanoma cells is consistent with results 
reported by Belanger et al. [39], wherein it was observed 
that (6-4)PP repair in response to UVB and UVC was 
slower in melanoma cell lines compared to melanocytes. 
While Gaddameedhi et al. [51] reported no difference in 
Table 1 Relative expression of Transcription coupled repair (TCR) and nucleotide excision repair (NER) transcripts in mel-
anocytes and melanoma cell lines following UVA
Gene Cell Type Time (h)
0 1 4 24 48
RE P value RE P value RE P value RE P value RE P value
Transcription coupled repair (TCR)
 ERCC6 Melanocytes 0.0883 NS 0.0000 <0.001 0.1079 NS 0.0236 <0.001 0.3084 NS
Melanoma 0.1345 0.1003 0.1534 0.1715 0.2396
 ERCC8 Melanocytes 0.0893 NS 0.0000 <0.001 0.1026 NS 0.0251 <0.001 0.1102 NS
Melanoma 0.1707 0.0586 0.0780 0.0482 0.0980
Nucleotide excision repair (NER)
 XPA Melanocytes 0.1288 0.03 0.2592 <0.001 0.5513 <0.001 0.1530 NS 0.5681 NS
Melanoma 0.0924 0.1161 0.1447 0.2406 0.3585
 RPA1 Melanocytes 0.4713 0.02 0.3281 <0.001 1.1675 NS 0.9926 0.038 4.1019 NS
Melanoma 2.0848 1.3489 0.9849 2.4304 2.1699
 RPA2 Melanocytes 0.2883 0.002 0.4576 0.002 1.3346 NS 0.4085 <0.001 1.5100 NS
Melanoma 1.7746 1.2359 1.2400 1.9103 1.6426
 ERCC1 Melanocytes 1.1466 NS 1.2102 NS 4.1937 <0.001 6.4460 <0.001 3.0374 0.04
Melanoma 1.1916 1.4276 1.5437 1.5859 2.2263
 ERCC2 Melanocytes 0.6308 NS 0.9042 0.007 1.7292 <0.001 0.8925 <0.001 1.1017 0.03
Melanoma 0.5406 0.4764 0.3694 0.4094 0.5468
 ERCC3 Melanocytes 0.1390 <0.001 0.7994 NS 0.8556 <0.001 0.2262 <0.001 1.0353 0.05
Melanoma 0.4889 0.4753 0.3632 0.6632 0.6733
 ERCC4 Melanocytes 0.1018 NS 0.0000 <0.001 0.1832 0.009 0.0000 <0.001 0.4600 NS
Melanoma 0.1977 0.1656 0.1709 0.2446 0.3675
 ERCC5 Melanocytes 0.0537 0.001 0.0000 <0.001 0.1138 NS 0.0000 <0.001 0.4116 NS
Melanoma 0.2245 0.2294 0.1160 0.2777 0.3699
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Fig. 3 Expression of global genome repair XPC, DDB1, and DDB2 following UVA irradiation in melanocytes and melanoma. Cell lines were irradiated 
with 100 kJ/m2 UVA, then mRNA transcript relative expression (RE) at baseline and 1, 4, 24, and 48 h post-irradiation was determined. a RE of XPC 
mRNA transcript b DDB1 mRNA transcript, c DDB2 mRNA transcript. Significance compared to melanocytes (HEMaLP) determined by Mann–Whit-
ney U test. *p < 0.05. Points mean of triplicate determinations of three independent experiments; bars ± SEM. d Western blot of XPC, DDB1 and 
DDB2 for all cell lines before and after UVA. Blots are representative of duplicate blots run for all proteins and cell lines
Fig. 4 Expression of p53 following UVA irradiation in melanocytes and melanoma. Cell lines were irradiated with 100 kJ/m2 UVA, then mRNA 
transcript relative expression (RE) at baseline and 1, 4, 24, and 48 h post-irradiation was determined. a RE of p53 mRNA transcript. Significance 
compared to melanocytes (HEMaLP) determined by Mann–Whitney U test. *p < 0.05. Points mean of triplicate determinations of three independent 
experiments; bars ± SEM. b Western blot of p53 for all cell lines before and after UVA. Blots are representative of duplicate blots run for all proteins 
and cell lines
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excision repair rates between melanoma and melanocyte 
cell strains in response to UVC, their study did not nor-
malise the amount of DNA damage to cell number; in 
contrast to Belanger et al. [39] and our study.
While CPDs have been largely considered to be pro-
duced by the direct absorption of UV energy by DNA 
[24], indirect production of CPDs following UVA and 
UVB exposure has recently been described. Premi et al. 
[52] have shown that UV induced reactive oxygen and 
nitrogen species react with melanin to produce a dioxe-
tane intermediate that may produce CPDs in the absence 
of light through energy transfer to DNA. This leads to the 
continued production of CPDs—termed “dark CPDs”—
for more than 3  h following UV exposure in melanin 
containing cells [52]. However, the magnitude of the dark 
CPD effect is variable between samples, possibly depend-
ent on inter-individual variation in level of melanin and 
melanin type. Interestingly, continued production of 
CPDs at early time points following UVA irradiation 
was observed in our study in melanoma cells only. It is 
not clear if melanocytes also produced dark CPDs that 
were rapidly repaired, this requires further investigation. 
Irrespective of this, the melanoma cell lines displayed 
delayed onset of repair to 24 h, resulting in a large accu-
mulation of CPDs.
The delayed induction of CPD repair after 24  h 
observed in melanoma cells corresponded with the 
delayed induction of GGR and p53 transcripts in 
response to UVA. Despite this, melanoma cells displayed 
a DDB2 protein induction profile comparable to melano-
cytes, and two (Sk-Mel-28, Mel-RM) of four melanoma 
cell lines displayed induction of DDB1 similar to normal 
melanocytes. Given the significantly lower DDB1 and 
DDB2 transcript expression observed in melanoma cells, 
this suggests enhanced translation rate or protein stabil-
ity of DDB1 and DDB2 in melanoma cells.
A notable difference between melanoma cell lines and 
melanocytes was observed for XPC protein expression. 
XPC transcript expression was significantly higher in 
melanocytes compared to all melanoma cell lines at 4 h. 
NER function is correlated with XPC expression [53], 
suggesting altered protein expression of XPC in mela-
noma may contribute to the observed reduced level of 
NER activity in melanoma.
Despite lower relative transcript expression, mela-
noma cell lines displayed a higher level of p53 protein 
induction compared to melanocytes. All cell lines except 
Me4405 (p53 null) displayed a similar p53 protein induc-
tion pattern; with expression peaking at 4 or 24 h follow-
ing UVA exposure. p53 is known to display abnormal 
function in melanoma, and is commonly overexpressed 
at the protein level [40, 54]. Whether this is a potential 
cause or consequence of reduced GGR in melanoma 
requires further studies. Our study confirms increased 
p53 expression does not directly result in increased NER 
in melanoma.
Fig. 5 Relative expression (RE) of GGR transcripts a XPC, b DDB1, and 
c DDB2 following UVA irradiation in p53- and p53 + melanoma cell 
lines. p53 mutant/null (p53−; Sk-Mel-28, Me4405) and p53 wildtype 
(p53+; MM200, Mel-RM melanoma cell lines were irradiated with 
100 kJ/m2 UVA, then RE at baseline and 1, 4, 24, and 48 h post-
irradiation was determined. Points mean of triplicate determinations 
of three independent experiments; bars ± SEM. Significant differ-
ences between groups were determined by Mann–Whitney U test. 
*p < 0.05, **p < 0.005, ***p < 0.000
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Within melanoma cell lines, significant differences in 
GGR transcript expression were seen in relation to p53 
mutation status. p53 is a known transcriptional regulator 
of GGR genes DDB2 and XPC. DDB2 expression was sig-
nificantly lower in p53 mutant/null cell lines compared to 
p53 wildtype melanoma cell lines, at all time points. Con-
versely, no significant difference in XPC expression was 
observed according to p53 status, and p53 mutant/null 
cells displayed comparatively higher expression of DDB1. 
Suggesting that overall expression of GGR is independent 
of p53.
The most dominant mutational signature seen in mela-
noma is C to T changes due to UVR [35, 55, 56]. Further 
investigation of the UVR mutational signature found a 
higher prevalence in lowly transcribed genes, suggest-
ing that reduced activity of the GGR component of the 
NER pathway is predominantly responsible for the 
accumulation of the UVR mutational signature in mela-
noma. The evidence to date, including this study sug-
gests TCR is fully functional in melanoma. To further 
support this finding we previously identified significantly 
lower mRNA expression of all the GGR related genes in 
melanoma cell lines compared to melanocytes [57] after 
cisplatin treatment, but there was no difference in TCR 
response. Taken together, the results of all these studies 
indicate that GGR is deficient in melanoma, a finding 
that is largely overlooked in clinical studies of the disease.
The finding of reduced NER function in melanoma has 
important clinical implications. In the childhood skin 
cancer disorder xeroderma pigmentosum (XP) DNA 
damage accumulates rapidly after UV-light exposure that 
is associated with the development of many skin cancers 
on sunlight exposed areas of skin. A distinguishing fea-
ture of XP resulting from GGR mutations is mutation 
accumulation across most of the genome, whereas TCR 
deficient disorders, such as Cockayne’s syndrome, involve 
only actively transcribed genes [58]. The consequence of 
involvement of the whole genome is an increased risk of 
developing cancer in patients with XP, whereas patients 
with Cockayne’s syndrome predominantly display neu-
rological symptoms with no increase in cancer incidence 
[58]. This is directly attributable to causative disease 
mutations being present in GGR genes, XPC and DDB2 
(XPE) in patients with XP, but not in the transcription 
coupled repair (TCR) genes CSA and CSB in Cockayne’s 
syndrome. Similarly, mutations in genes involved in the 
mismatch repair (MMR) pathway result in hereditary 
non-polyposis colorectal cancer (HNPCC) or Lynch Syn-
drome which is characterised primarily by increased risk 
of colorectal, endometrial and other cancers [59]. Recent 
studies have reported an increased response to anti-PD1 
immunotherapy in MMR-deficient cancers, suggesting 
that genomic instability plays a major role in the response 
[60]. Therefore, the deficiency in GGR reported in this 
study is likely to directly contribute to increased muta-
tions across the melanoma genome and the response to 
anti-PD1 immunotherapy.
DDB2 and XPC have been linked to the induction of 
apoptosis following UVB and cisplatin respectively, 
through mechanisms independent of p53 [48, 49]. Con-
sistent with this, DDB2-deficient cells have been shown 
to be resistant to UVB and cisplatin induced apop-
tosis [61, 62]. Therefore, reduced GGR may not only 
lead to the high mutation signature of melanoma, but 
may also facilitate survival of mutant cells and enhance 
chemoresistance.
Conclusions
This is the first study to show that an easily obtainable 
dose of UVA is sufficient to induce CPD formation fol-
lowed by rapid repair and GGR transcript and protein 
expression increases in normal melanocytes. The same 
GGR response was not observed in melanoma, resulting 
in CPD repair deficiency and an accumulation of damage 
48 h after UVA. This study is the first to provide evidence 
that NER deficiency in melanoma is responsible for the 
high C  >  T mutation load as a result of UVA exposure 
and has implications for resistance to DNA-damaging 
chemotherapy such as cisplatin.
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